0000899243-21-001378.txt : 20210111 0000899243-21-001378.hdr.sgml : 20210111 20210111175909 ACCESSION NUMBER: 0000899243-21-001378 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210108 FILED AS OF DATE: 20210111 DATE AS OF CHANGE: 20210111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leggett Thomas CENTRAL INDEX KEY: 0001774690 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 21521844 MAIL ADDRESS: STREET 1: C/O AXCELLA HEALTH INC. STREET 2: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-08 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001774690 Leggett Thomas C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 10TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 Chief Financial Officer Common Stock 2021-01-08 4 M 0 3000 10.86 A 3000 D Common Stock 2021-01-08 4 S 0 3000 33.94 D 0 D Stock Option (Right to Buy) 10.86 2021-01-08 4 M 0 3000 0.00 D 2029-09-08 Common Stock 3000 218171 D Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $34.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. /s/ Brent Hatzis-Schoch, as Attorney-in-Fact 2021-01-11